SAB Biotherapeutics is a clinical-stage company developing SAB-142, a fully human anti-thymocyte immunoglobulin meant to preserve insulin production in newly diagnosed type 1 diabetes; it is not approved.
SAB's case rests on SAB-142, a fully human anti-thymocyte immunoglobulin produced using transchromosomic cattle, potentially preserving insulin production in newly diagnosed Stage 3 type 1 diabetes. Registrational Phase 2b SAFEGUARD remains the key efficacy milestone, with enrollment expected in Q4 2026 and topline data in 2H 2027. Fast Track may facilitate development, but does not establish efficacy or approval. Separate investigator-led Phase 3 PRISE-hATG explores later treatment. June cash and investments totaled about $208 million after the March offering; long-term plans require additional capital.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: SAFEGUARD preserves insulin production versus placebo
Does SAB-142 preserve insulin production versus placebo with an acceptable safety profile in newly diagnosed Stage 3 diabetes?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
SAB-142 gains Fast Track; SAFEGUARD efficacy data remain the key milestone
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.